Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
2(11%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
16
84%
Ph phase_1
1
5%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
1(5.9%)
N/ANon-phased studies
16(94.1%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

94.1%

16 of 17 finished

Non-Completion Rate

5.9%

1 ended early

Currently Active

2

trials recruiting

Total Trials

19

all time

Status Distribution
Active(2)
Completed(16)
Terminated(1)

Detailed Status

Completed16
Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
2
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (5.9%)
N/A16 (94.1%)

Trials by Status

withdrawn15%
completed1684%
recruiting211%

Recent Activity

2 active trials
Showing 5 of 19
recruitingphase_1

Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

NCT06205849
recruiting

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-

NCT06937996
completednot_applicable

Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma

NCT03105921
completednot_applicable

Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms

NCT02430623
completednot_applicable

Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms

NCT02335112
View all 19 trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT06205849Phase 1

Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

Recruiting
NCT06937996

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-

Recruiting
NCT03105921Not Applicable

Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma

Completed
NCT02430623Not Applicable

Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms

Completed
NCT02335112Not Applicable

Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms

Completed
NCT02430779Not Applicable

Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms

Completed
NCT02430610Not Applicable

Irreversible Electroporation(IRE) For Uterine Cervical Neoplasms

Completed
NCT02430766Not Applicable

Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases(Close to Nerve)

Completed
NCT02430701Not Applicable

Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms

Completed
NCT02332551Not Applicable

Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder

Completed
NCT02430636Not Applicable

Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms

Completed
NCT02430675Not Applicable

Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms

Completed
NCT02425059Not Applicable

Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms

Completed
NCT02430753Not Applicable

Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency

Completed
NCT02430662Not Applicable

Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms

Completed
NCT02430597Not Applicable

Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms

Completed
NCT02430688Not Applicable

Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms

Completed
NCT02430649Not Applicable

Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms

Withdrawn
NCT02079623

Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer

Completed

All 19 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
19